Transcranial optical imaging reveals a pathway for optimizing the delivery of immunotherapeutics to the brain
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Despite the initial promise of immunotherapy for CNS disease, multiple recent clinical trials have failed. This may be due in part to characteristically low penetration of antibodies to cerebrospinal fluid (CSF) and brain parenchyma, resulting in poor target engagement. We here utilized transcranial macroscopic imaging to noninvasively evaluate in vivo delivery pathways of CSF fluorescent tracers. Tracers in CSF proved to be distributed through a brain-wide network of periarterial spaces, previously denoted as the glymphatic system. CSF tracer entry was enhanced approximately 3-fold by increasing plasma osmolality without disruption of the blood-brain barrier. Further, plasma hyperosmolality overrode the inhibition of glymphatic transport that characterizes the awake state and reversed glymphatic suppression in a mouse model of Alzheimer's disease. Plasma hyperosmolality enhanced the delivery of an amyloid-β (Aβ) antibody, obtaining a 5-fold increase in antibody binding to Aβ plaques. Thus, manipulation of glymphatic activity may represent a novel strategy for improving penetration of therapeutic antibodies to the CNS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“Perhaps the most notable application of mAb is seen in efforts to enhance amyloid-β (Aβ) clearance from brain (4, 6, 7).”
Iliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824
Self-citationSleep Drives Metabolite Clearance from the Adult Brain
Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., O’Donnell, J., Christensen, D. J., Nicholson, C., Iliff, J. J., et al. (2013) · Science · doi:10.1126/science.1241224 · Cited by 5,411
Self-citationThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 4×
“Tracer and antibody penetration were also quantified ex vivo in coronal sections, as described previously (1).”
InfluentialThe glymphatic system: a beginner's guide
Jessen, N. A., Munk, A. S. F., Lundgaard, I., & Nedergaard, M. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1581-6 · Cited by 2,075
Self-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 1×
“than the concentration needed to achieve adequate binding of the target antigen in peripheral tissues (1, 17), and these high doses in clinical trials increase the prevalence of adverse events (1, 9, 18) such as amyloid-related imaging abnormalities (ARIA) (19, 20).”
Impairment of paravascular clearance pathways in the aging brain
Kress, B. T., Iliff, J. J., Xia, M., Wang, M., Wei, H. S., Zeppenfeld, D., Xie, L., Kang, H., Xu, Q., Liew, J. A., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24271 · Cited by 1,521 · cited 4×
“While the role of the glymphatic pathway both in the clearance (21, 28, 29, 38, 41, 42) and delivery (21, 39, 43–48) of solutes has been established by multiple groups, prior studies using fluorescent, radiolabeled, and gadolinium-based tracers also suggest that convective flow through this pathway might be exploited…”
InfluentialSelf-citationCerebral Arterial Pulsation Drives Paravascular CSF–Interstitial Fluid Exchange in the Murine Brain
Iliff, J. J., Wang, M., Zeppenfeld, D. M., Venkataraman, A., Plog, B. A., Liao, Y., Deane, R., & Nedergaard, M. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1592-13.2013 · Cited by 1,319 · cited 2×
“The fast, convective fluid flow within the glymphatic system effectively delivers solutes of high-molecular weight (21) but is strongly regulated by brain state (28), aging (29), arterial pulsatility (30), and body posture (31).”
Self-citationBrain-wide pathway for waste clearance captured by contrast-enhanced MRI
Iliff, J. J., Lee, H., Yu, M., Feng, T., Logan, J., Nedergaard, M., & Benveniste, H. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67677 · Cited by 1,148
Self-citationTrial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 1×
“Despite promising preclinical results with this approach, results of clinical trials have been unimpressive and plagued by adverse events (8–10).”
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · cited 3×
“While the human mAb, aducanumab, induced dose-dependent reduction in soluble and insoluble A β and slowed clinical decline in prodromal or mild AD patients, ARIA emerged as a major issue, limiting intravenous dosing (1).”
Rennels, M. L., Gregory, T. F., Blaumanis, O. R., Fujimoto, K., & Grady, P. A. (1985) · Brain Research · doi:10.1016/0006-8993(85)91383-6 · Cited by 752
Aquaporin-4-dependent glymphatic solute transport in the rodent brain
Mestre, H., Hablitz, L. M., Xavier, A. L., Feng, W., Zou, W., Pu, T., Monai, H., Murlidharan, G., Castellanos Rivera, R. M., Simon, M. J., et al. (2018) · eLife · doi:10.7554/elife.40070 · Cited by 738 · cited 2×
“Confirming previously reported findings (21, 28, 37–39), there was significantly less glymphat-ic influx in both the awake and KX-Aqp4 –/– groups compared with that in the KX mice (Figure 1, C and D, and Supplemental Video 1).”
Self-citationGlymphatic MRI in idiopathic normal pressure hydrocephalus
Ringstad, G., Vatnehol, S. A. S., & Eide, P. K. (2017) · Brain · doi:10.1093/brain/awx191 · Cited by 722 · cited 1×
“While the role of the glym-phatic pathway both in the clearance (21, 28, 29, 38, 41, 42) and delivery (21, 39, 43–48) of solutes has been established by multiple groups, prior studies using fluorescent, radiolabeled, and gadolinium-based tracers also suggest that convective flow through this…”
Ma, Q., Ineichen, B. V., Detmar, M., & Proulx, S. T. (2017) · Nature Communications · doi:10.1038/s41467-017-01484-6 · Cited by 690
Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease
Peng, W., Achariyar, T. M., Li, B., Liao, Y., Mestre, H., Hitomi, E., Regan, S., Kasper, T., Peng, S., Ding, F., et al. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.05.015 · Cited by 580 · cited 2×
“The HTS reversed the glymphatic impairment previously documented in the APP/PS1+/– mice (35) and provoked significantly increased anti-Aβ antibody delivery throughout the cerebrum relative to that in the isotonic controls (P = 0.”
Self-citationDeletion of aquaporin-4 in APP/PS1 mice exacerbates brain Aβ accumulation and memory deficits
Xu, Z., Xiao, N., Chen, Y., Huang, H., Marshall, C., Gao, J., Cai, Z., Wu, T., Hu, G., & Xiao, M. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0056-1 · Cited by 500 · cited 1×
“Present observations also extend the prior finding that genetic deletion of AQP4 in APP/PS1-transgenic mice accelerated cognitive decline and amyloid burden (54).”
Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo
Klyubin, I., Walsh, D. M., Lemere, C. A., Cullen, W. K., Shankar, G. M., Betts, V., Spooner, E. T., Jiang, L., Anwyl, R., Selkoe, D. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1234 · Cited by 489
The Effect of Body Posture on Brain Glymphatic Transport
Lee, H., Xie, L., Yu, M., Kang, H., Feng, T., Deane, R., Logan, J., Nedergaard, M., & Benveniste, H. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1625-15.2015 · Cited by 456
Self-citationA Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
DeMattos, R. B., Lu, J., Tang, Y., Racke, M. M., DeLong, C. A., Tzaferis, J. A., Hole, J. T., Forster, B. M., McDonnell, P. C., Liu, F., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.10.029 · Cited by 442 · cited 1×
“Our study also used substantially less antibody than required in previous studies, while achieving greater target engagement (27, 58).”
Klunk, W. E., Bacskai, B. J., Mathis, C. A., Kajdasz, S. T., McLellan, M. E., Frosch, M. P., Debnath, M. L., Holt, D. P., Wang, Y., & Hyman, B. T. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.9.797 · Cited by 412
Direct neuronal glucose uptake heralds activity-dependent increases in cerebral metabolism
Lundgaard, I., Li, B., Xie, L., Kang, H., Sanggaard, S., Haswell, J. D. R., Sun, W., Goldman, S., Blekot, S., Nielsen, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms7807 · Cited by 381
Self-citationSmith, A. J., Yao, X., Dix, J. A., Jin, B.-J., & Verkman, A. S. (2017) · eLife · doi:10.7554/elife.27679 · Cited by 362 · cited 1×
“The recent critique of the key role of AQP4 in glymphatic function (40) has been challenged by a recent study from 4 independent labs demonstrating an essential role of AQP4 in solute dispersion in the mouse brain (37).”
Yang, L., Kress, B. T., Weber, H. J., Thiyagarajan, M., Wang, B., Deane, R., Benveniste, H., Iliff, J. J., & Nedergaard, M. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-107 · Cited by 317 · cited 1×
“Prior studies of CSF interstitial fluid (ISF) exchange within the glymphatic system have utilized ex vivo conventional fluorescence microscopy and in vivo 2-photon microscopy to image CSF- or ISF-based tracer fluxes (21, 22, 28, 29, 35, 36).”
Self-citationImpairment of the glymphatic system after diabetes
Jiang, Q., Zhang, L., Ding, G., Davoodi-Bojd, E., Li, Q., Li, L., Sadry, N., Nedergaard, M., Chopp, M., & Zhang, Z. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16654702 · Cited by 308 · cited 1×
“While the role of the glymphatic pathway both in the clearance (21, 28, 29, 38, 41, 42) and delivery (21, 39, 43–48) of solutes has been established by multiple groups, prior studies using fluorescent, radiolabeled, and gadolinium-based tracers also suggest that convective flow through this pathway might be exploited…”
Self-citationBapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Vandenberghe, R., Rinne, J. O., Boada, M., Katayama, S., Scheltens, P., Vellas, B., Tuchman, M., Gass, A., Fiebach, J. B., Hill, D., et al. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0189-7 · Cited by 304
Pizzo, M. E., Wolak, D. J., Kumar, N. N., Brunette, E., Brunnquell, C. L., Hannocks, M., Abbott, N. J., Meyerand, M. E., Sorokin, L., Stanimirovic, D. B., et al. (2018) · The Journal of Physiology · doi:10.1113/jp275105 · Cited by 272 · cited 5×
“Although antibodies show limited diffusive transport in the CNS extracellular space (26, 27), harnessing perivascular and parenchymal convective flows could potentially enhance their delivery into the brain.”
InfluentialActive and passive immunotherapy for neurodegenerative disorders
Brody, D. L., & Holtzman, D. M. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.31.060407.125529 · Cited by 250 · cited 1×
“may contribute to the lack of translation of these therapies into routine AD treatment (4, 12).”
Benveniste, H., Lee, H., Ding, F., Sun, Q., Al-Bizri, E., Makaryus, R., Probst, S., Nedergaard, M., Stein, E. A., & Lu, H. (2017) · Anesthesiology · doi:10.1097/aln.0000000000001888 · Cited by 236
Self-citationCserr, H. F., DePasquale, M., Nicholson, C., Patlak, C. S., Pettigrew, K. D., & Rice, M. E. (1991) · The Journal of Physiology · doi:10.1113/jphysiol.1991.sp018793 · Cited by 141
Thakker, D. R., Weatherspoon, M. R., Harrison, J., Keene, T. E., Lane, D. S., Kaemmerer, W. F., Stewart, G. R., & Shafer, L. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813404106 · Cited by 124 · cited 5×
“As a result, therapeutic antibodies are often given at doses 1,000-fold greater than the concentration needed to achieve adequate binding of the target antigen in peripheral tissues (1, 17), and these high doses in clinical trials increase the prevalence of adverse events (1, 9, 18) such as amyloid-related imaging abn…”
InfluentialGlymphatic fluid transport controls paravascular clearance of AAV vectors from the brain
Murlidharan, G., Crowther, A., Reardon, R. A., Song, J., & Asokan, A. (2016) · JCI Insight · doi:10.1172/jci.insight.88034 · Cited by 72
Research works printed but not linked: 28
- 10.1002/mds.26878 · DOI · Paper page
- Gros-Louis, 2010, Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS, J Neurochem, 113, 1188, 10.1111/j.1471-4159.2010.06683.x · DOI · Paper page
- Gallardo, 2017, Antibody therapeutics targeting Aβ and Tau, Cold Spring Harb Perspect Med, 7, 10.1101/cshperspect.a024331 · DOI · Paper page
- 10.1200/JCO.2017.72.8089 · DOI · Paper page
- 10.1016/j.pharmthera.2014.05.009 · DOI · Paper page
- 10.1016/j.pediatrneurol.2016.10.022 · DOI · Paper page
- 10.1186/alzrt220 · DOI · Paper page
- 10.1016/S0196-9781(02)00261-9 · DOI · Paper page
- 10.1016/j.expneurol.2007.05.005 · DOI
- Salloway, 2014, Phase 3 trials of solanezumab and bapineuzumab for Alzheimer’s disease, N Engl J Med, 370
- Rennels, 1990, Rapid solute transport throughout the brain via paravascular fluid pathways, Adv Neurol, 52, 431
- 10.1016/j.jconrel.2014.10.034 · DOI · Paper page
- Pullen, 1987, Bulk flow of cerebrospinal fluid into brain in response to acute hyperosmolality, Am J Physiol, 253, F538
- Cserr, 1987, Volume regulatory influx of electrolytes from plasma to brain during acute hyperosmolality, Am J Physiol, 253, F530
- 10.1177/0271678X16661202 · DOI · Paper page
- 10.1186/s13024-016-0138-8 · DOI · Paper page
- Rangroo Thrane, 2013, Paravascular microcirculation facilitates rapid lipid transport and astrocyte signaling in the brain, Sci Rep, 3
- 10.1016/j.neurobiolaging.2016.11.002 · DOI · Paper page
- 10.1161/STROKEAHA.114.006617 · DOI · Paper page
- Brain Trauma Foundation, 2007, Guidelines for the management of severe traumatic brain injury. II. Hyperosmolar therapy, J Neurotrauma, 24 Suppl 1, S14
- 10.1177/0271678X16655550 · DOI · Paper page
- Muizelaar, 1984, Effect of mannitol on ICP and CBF and correlation with pressure autoregulation in severely head-injured patients, J Neurosurg, 61, 700, 10.3171/jns.1984.61.4.0700 · DOI · Paper page
- Domaingue, 1985, Hypotensive effect of mannitol administered rapidly, Anaesth Intensive Care, 13, 134, 10.1177/0310057X8501300204 · doi:10.1177/0310057x8501300204
- 10.1186/alzrt233 · DOI · Paper page
- 10.1063/1.4979668 · DOI
- 10.1016/j.jneumeth.2016.04.012 · DOI · Paper page
- 10.1038/nmeth.2089 · DOI · Paper page
- 10.1038/nmeth.2019 · DOI · Paper page
Cited by
Aquaporin-4-dependent glymphatic solute transport in the rodent brain
Mestre, H., Hablitz, L. M., Xavier, A. L., Feng, W., Zou, W., Pu, T., Monai, H., Murlidharan, G., Castellanos Rivera, R. M., Simon, M. J., et al. (2018) · eLife · doi:10.7554/elife.40070 · Cited by 738
Self-citationCircadian control of brain glymphatic and lymphatic fluid flow
Hablitz, L. M., Plá, V., Giannetto, M., Vinitsky, H. S., Stæger, F. F., Metcalfe, T., Nguyen, R., Benrais, A., & Nedergaard, M. (2020) · Nature Communications · doi:10.1038/s41467-020-18115-2 · Cited by 704
Self-citationThe Brain’s Glymphatic System: Current Controversies
Mestre, H., Mori, Y., & Nedergaard, M. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.04.003 · Cited by 609
Self-citationRasmussen, M. K., Mestre, H., & Nedergaard, M. (2022) · Physiological Reviews · doi:10.1152/physrev.00031.2020 · Cited by 597
Self-citationCerebrospinal fluid influx drives acute ischemic tissue swelling
Mestre, H., Du, T., Sweeney, A. M., Liu, G., Samson, A. J., Peng, W., Mortensen, K. N., Stæger, F. F., Bork, P. A. R., Bashford, L., et al. (2020) · Science · doi:10.1126/science.aax7171 · Cited by 494
Self-citation
Metadata
- Authors
- Plog, B. A., Mestre, H., Olveda, G. E., Sweeney, A. M., Kenney, H. M., Cove, A., Dholakia, K. Y., Tithof, J., Nevins, T. D., Lundgaard, I., Du, T., Kelley, D. H., & Nedergaard, M.
- Venue
- JCI Insight
- Published
- 2018-10-18
- Volume
- 3
- Issue
- 20
- ISSN
- 2379-3708 (ISSN-L)
- OpenAlex
- W2896444937
- Cited by
- 101
- References
- 33
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- National Institutes of Health (5R01NS100366-02, 1RF1AG057575-01)
- U.S. Department of Defense (Science,Engineering Graduate Fellowship)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.